Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Announced first patient dosed in the Phase 2b placebo-controlled portion of the…
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq:…
Everhope Oncology Launches First Cancer Daycare Centre in Gurugram — Revolutionizing Cancer Care with Compassion, Precision and Convenience
Everhope Oncology takes the anxiety out of cancer treatment — with zero…
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information…
Intas Pharmaceuticals Launches HETRONIFLY (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer
AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™…
Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors
BEIJING, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the…
FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Proven efficacy across all three key markers of disease—68% reduction in proteinuria,…
Testosterone Booster for Muscle Gain: Men Opt for OTC Supplement Form Natural Testosterone Replacement Therapy (TRT) Treatment in 2025
New York City, NY, July 27, 2025 (GLOBE NEWSWIRE) -- A recent…
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
– Phase 1a clinical data in healthy participants presented for both ABI-5366…
Landmark Trial Demonstrates Efficacy of Microcurrent Therapy in Heart Failure: C-MIC II Results Published in the European Journal of Heart Failure
ZUG, Switzerland, July 23, 2025 /PRNewswire/ -- Berlin Heals and the C-MIC II…